Evaluation of the prognostic value of cellular, inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis
Evaluation of the prognostic value of cellular, inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis
复制标题
DOI：
10.1158/1055-9965.epi-06-0120
复制
发表时间：
2006-06-01
影响因子：
3.8
通讯作者：
Dimopoulos, Meletios A.
中科院分区：
文献类型：
--
作者：
Psyrri, Amanda;Yu, Ziwei;Dimopoulos, Meletios A.
目的：细胞凋亡抑制蛋白（cIAP）被认为是一种重要的肿瘤预后生物标志物。在这里，我们试图确定cIAP蛋白水平在上皮性卵巢癌中的预后价值，使用一种新的方法，划分原位蛋白analysis.Methods：组织阵列组成的150个晚期卵巢癌，手术减积，然后铂/紫杉醇为基础的联合化疗，构建。对于蛋白质表达的评价，我们使用了免疫荧光为基础的方法的自动化原位定量测量的蛋白质analysis.Results：平均随访时间为整个队列为34.4个月。cIAP膜表达高的肿瘤患者3年生存率为31%，而cIAP表达低的肿瘤患者为73%（P = 0.0020）。在多变量分析中，调整良好的预后变量，低膜cIAP表达水平是唯一显着的预后因素为总survival.Conclusions：我们的研究结果表明，cIAP蛋白水平在卵巢癌患者的预后价值。调节cIAP水平可能改善卵巢癌的临床结局。
Purpose: The cellular inhibitor of apoptosis protein (cIAP) is regarded as an important prognostic biomarker in cancer. Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis.Methods: A tissue array composed of 150 advanced-stage ovarian cancers, treated with surgical debulking followed by platinum/paclitaxel-based combination chemotherapy, was constructed. For evaluation of protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis.Results: The mean follow-up time for the entire cohort was 34.4 months. Patients with tumors bearing high cIAP membranous expression had a 3-year survival rate of 31% compared with 73% for patients with low cIAP expressing tumors (P = 0.0020). In multivariable analysis, adjusting for well-characterized prognostic variables, low membranous cIAP expression level was the only significant prognostic factor for overall survival.Conclusions: Our results indicate that cIAP protein levels have prognostic value in ovarian cancer patients. Modulation of cIAP levels may improve clinical outcome in ovarian cancer.